Eli Lilly and Company’s investigational neutralizing antibody bamlanivimab has not been endorsed, at least not immediately, by an Indian expert panel as a treatment for COVID-19 via the expedited trial waiver route.
The no-go by the Indian Subject Expert Committee (SEC) came even as the drug received an Emergency Use Authorization (EUA)...







